MNPR
NASDAQMonopar Therapeutics Inc.
Price$59.58+3.81 (+6.83%)
2026-03-042026-06-05
News · 26 weeks34-50%
2025-12-142026-06-07
Mix1890d
- SEC Filings10(56%)
- Other5(28%)
- Insider2(11%)
- Offering1(6%)
Latest news
25 items- PRMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation (link) of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver (EASL) Congress 2026. In a presentation titled "ALXN1840 (tiomolibdate choline) Stabilizes Liver Disease and Improves Neurological Symptoms as well as Quality of Life in Treatment-Experienced Wilson Disease Patients," lead author Valentina Medici, MD, Professor of Medicine at the University of California Davis, presented results from
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseWILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that Hepatology Communications has published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial." The publication, which can be found at (link), reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily cop
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-Q filed by Monopar Therapeutics Inc.10-Q - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesWILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at the American Academy of Neurology (AAN) Annual Meeting 2026. The late-breaker oral and poster presentation, titled "Greater clinical benefit w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECSEC Form DEFA14A filed by Monopar Therapeutics Inc.DEFA14A - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form DEF 14A filed by Monopar Therapeutics Inc.DEF 14A - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled "Greater clinical benefit with t
- INSIDERSEC Form 4 filed by Robinson Chandler4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Cittadine Andrew4 - Monopar Therapeutics (0001645469) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.10-K/A - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-K filed by Monopar Therapeutics Inc.10-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateWILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt
- INSIDERSEC Form 4 filed by CCSO Rodriguez Susan4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rodriguez Susan3 - Monopar Therapeutics (0001645469) (Issuer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerWILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- INSIDERChief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
MNPR FAQ
7 questionsWhat does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a...Where does MNPR stock trade?
Monopar Therapeutics Inc. (MNPR) is listed on NASDAQ.What sector and industry is MNPR in?
Monopar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Monopar Therapeutics Inc. go public?
Monopar Therapeutics Inc. (MNPR) completed its IPO in 2019.What are analysts saying about MNPR?
Monopar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight on 2026-01-09.What companies are similar to MNPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MNPR side-by-side with any of them on Quantisnow.How can I track MNPR on Quantisnow?
Quantisnow aggregates Monopar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNPR to receive live email and push alerts on every new disclosure.